Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9870004 | 0.84 | TDP1 (0.42) | TDP1TSHRL3MBTL1GPR35ALDH1A1 | |
| SCHEMBL7321325 | 0.80 | ALDH1A1 (0.45) | TDP1TSHRMAPTALDH1A1KMT2A | |
| SCHEMBL8011477 | 0.80 | ALDH1A1 (0.43) | TDP1TSHRL3MBTL1GPR35ALDH1A1 | |
| SCHEMBL10731956 | 0.76 | GPR35 (0.42) | TDP1TSHRL3MBTL1GPR35CASP6 | |
| SCHEMBL27752933 | 0.75 | FBP1 (0.45) | TDP1TSHRL3MBTL1CASP6MAPT | |
| SCHEMBL41322 | 0.75 | GPR35 (0.54) | TDP1TSHRL3MBTL1GPR35MAPT | |
| SCHEMBL33832 | 0.72 | TDP1 (0.46) | TDP1TSHRL3MBTL1GPR35ALDH1A1 | |
| SCHEMBL7136437 | 0.72 | TDP1 (0.46) | TDP1TSHRL3MBTL1GPR35ALDH1A1 | |
| SCHEMBL9771589 | 0.72 | ALDH1A1 (0.44) | MAPTALDH1A1KMT2AGAA | |
| SCHEMBL2075134 | 0.71 | TDP1 (0.45) | TDP1TSHRGPR35ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197898-A1 | SUBSTITUTED BENZO[5,6][1,4]DIAZEPINO[1,2-a]INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | IMMUNOGEN, INC. | 2024-06-20 | — | — | US | claimed |
| CN-117065043-A | Method for preventing oxidation of methionine in immunoconjugates | 伊缪诺金公司 | 2023-11-17 | — | — | CN | claimed |
| CN-116514903-A | Cytotoxic benzodiazepine derivatives | 伊缪诺金公司 | 2023-08-01 | — | — | CN | claimed |
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-07-27 | — | — | US | claimed |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | IMMUNOGEN, INC. (US) | 2023-03-30 | — | — | US | claimed |
| CN-106604927-B | Cytotoxic benzodiazepine derivatives | 伊缪诺金公司 | 2022-08-09 | — | — | CN | claimed |
| US-20220153713-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2022-05-19 | — | — | US | claimed |
| US-20220153688-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2022-05-19 | — | — | US | claimed |
| EP-3992185-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) | 2022-05-04 | — | — | EP | claimed |
| EP-3992184-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) | 2022-05-04 | — | — | EP | claimed |
| WO-2012112708-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES AND METHODS OF PREPARATION | IMMUNOGEN, INC. (US) | 2012-08-23 | — | — | WO | claimed |
| WO-2012061590-A1 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES | IMMUNOGEN, INC. (US) | 2012-05-10 | — | — | WO | claimed |
| CN-101282974-A | Benzimidazole derivatives as SIRTUIN modulators | SIRTRIS PHARMACEUTICALS INC (US) | 2008-10-08 | — | — | CN | claimed |
| EP-1910362-A1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | claimed |
| WO-2007019345-A1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| US-6399292-B2 | A MATTING AGENT HAVING A SOFTENING TEMPERATURE OF FROM 100 TO 500 DEGREES C. IS CONTAINED AT LEAST ON ONE SIDE OF THE SUPPORT. | FUJI PHOTO FILM CO., LTD. (JP) | 2002-06-04 | — | — | US | claimed |
| US-20020015924-A1 | PHOTOTHERMOGRAPHIC PHOTOSENSITIVE MATERIAL AND PHOTOTHEMOGRAPHIIC METHOD | FUJIFILM CORPORATION (JP) | 2002-02-07 | — | — | US | claimed |
| EP-0277725-A2 | 4-Aryl-N-[2-(dialkylamino and heterocyclicamino) alkyl]-1-piperazinecarboxamides and their use as anti allergy agents | A.H. ROBINS COMPANY, INCORPORATED (US) | 1988-08-10 | — | — | EP | claimed |
| US-4021245-A | GELATION DERIVATIVE, SILICIC ACID ANHYDRIDE | FUJI PHOTO FILM CO., LTD. (JA) | 1977-05-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | TDP1 613/4885TSHR 3079/4885L3MBTL1 925/4885 |
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | TDP1 2165/4885TSHR 889/4885L3MBTL1 2374/4885 |
| US-20240197898-A1 | SUBSTITUTED BENZO[5,6][1,4]DIAZEPINO[1,2-a]INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | MKI67, GABBR1, GABBR2 | TDP1 1612/4885TSHR 879/4885L3MBTL1 3285/4885 |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | GABBR2, GABRB1, GABRB2 | TDP1 1899/4885TSHR 269/4885L3MBTL1 984/4885 |
| US-20220153688-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | SOST, HDAC5, PTH1R | TDP1 4527/4885TSHR 1218/4885L3MBTL1 4830/4885 |
| US-20220153713-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | FH, HDGF, HRH4 | TDP1 4725/4885TSHR 1288/4885L3MBTL1 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.